Strong tablets—small, largely spherical, and simple to swallow—are a tried and true drug formulation, and making them contributes to a lot of Catalent’s income. However shopper spending on dietary and nutraceutical merchandise is rising, and with it, demand for softer and even chewable formulations. Catalent needs to chunk off an enormous chunk of this market, so the contract drug producer has dedicated $1 billion to acquire Bettera Brands, an organization specializing in such merchandise.
Catalent introduced the Bettera acquisition on Monday, concurrent with its report of fiscal fourth quarter 2021 financial results. Catalent stated its web income in fiscal 2021 was almost $4 billion—a 29% enhance over the prior 12 months. The overwhelming majority of that income got here from its enterprise section producing organic medicine, the most important division of the Somerset, New Jersey-based firm.